- Thermo Fisher extends deadline for Dionex shares
Thermo Fisher Scientific Inc. (NYSE:TMO) announced that its previously announced tender offer to acquire all of the outstanding shares of Dionex Corp. (NSDQ:DNEX) for $118.50 per share in cash has been extended and will now expire at 12:00 midnight (EDT), at the end of Feb. 16, unless further extended. All other terms and conditions of the offer remain unchanged. As of 5:00 p.m. on January 13, 2011, approximately 3.5 million shares of Dionex common stock, representing approximately 20 percent of all outstanding shares, had been tendered into and not withdrawn from the offer.
Thermo Fisher anticipates completing the acquisition later in the first quarter of 2011.
- EI takes 50 percent stake in Wanxin Optical
Essilor International (Paris:EI), announced it is taking a 50 percent stake in Wanxin Optical, one of China’s leading manufacturers of ophthalmic lenses, as part of a joint venture agreement. Wanxin Optical has more than 2,000 employees, produces nearly 35 million lenses a year and generates annual revenue of approximately €24 million. Intended for both the domestic and export markets, its products are highly regarded by eyecare professionals, especially in the mid-range segment. Wanxin Optical will continue to be led by its current management team.
- Technest Holdings Inc. looks set to acquire AccelPath LLC
Technest Holdings, Inc. (OTC:TCNH) announced that it entered into a definitive unit purchase agreement in which the company agreed to acquire all of the outstanding membership interests of AccelPath LLC, a provider of digital telepathology and other services to laboratories and hospitals, directly from its members, in consideration for 86,151,240 newly-issued shares of Technest’s common stock in the aggregate. Immediately following this transaction, the former AccelPath members will beneficially own approximately 72.5 percent of Technest’s issued and outstanding common stock. The transaction is expected to close in Feb. 2011.
- ICON picks up Oxford Outcomes
ICON plc (NSDQ:ICLR), a provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the expansion of its Late Phase and Outcomes Research services through the acquisition of Oxford Outcomes, a leading international health outcomes consultancy. Elizabeth Thiele, formerly ICON’s executive vice president of business development, has been appointed president of this specialized service unit. Headquartered in Oxford, United Kingdom, and with offices in the U.S. and Canada, Oxford Outcomes provides specialist services in the areas of patient reported outcomes, health economics, epidemiology and translation and linguistic validation.